

SAMPLE FLOW REPORT

DIAGNOSIS:

ABC Hospital (Specimen A08-78910) (Collection Date: 6/1/08) (Collection Time: PM)


Bone marrow aspirate:


1. No significant immunophenotypic abnormalities of myeloid cell populations.
2. No abnormal B or T cell populations identified (see comment).

COMMENTS:

No significant immunophenotypic evidence of a myeloid stem cell disorder or non-Hodgkin lymphoma is identified. However, a low-grade myelodysplastic syndrome or chronic phase myeloproliferative disorder cannot be entirely excluded by flow cytometry. Therefore, correlation with the clinical history (e.g., excluding folate or B12 deficiency), and with the morphology of well-prepared bone marrow aspirate smears and biopsy sections, including iron stains, is recommended to address the possibility of a myeloid stem cell neoplasm. Cytogenetic evaluation of the marrow aspirate could also be performed to rule out a clonal stem cell abnormality.

RESULTS:





Immunophenotyping by flow cytometry after lysis of the erythroid cells reveals that the white blood cells consist of 15% lymphocytes, 0.5% monocytes, 78% maturing granulocytes, 3.3% blasts/basophils (1.1% CD34+blasts), and 0.3% plasma cells. The lymphocytes consist of 9.8% B cells (CD19+), 77% T cells (CD5+), and 10% NK cells (CD5-, CD38+, CD56+). The mature B cells show a normal kappa:lambda ratio of 37:24. The T cells show a normal CD4:CD8 ratio of 72:25.

Antibodies used: CD10: CD117: CD123: CD13: CD14: CD15: CD16: CD19: CD2: CD20: CD3: CD33: CD34: CD38: CD4: CD45: CD5: CD56: CD64: CD7: CD71: CD8: HLA-DR: Kappa (surface): Lambda (surface) (25)

• Electronically signed 06/04/2008: Steven J. Kussick, MD, PhD, Pathologist

Per CMS regulations, the pathologist's signature above indicates that this case has been reviewed and the diagnosis made or confirmed by said pathologist.

NOTE: Some of the tests reported here may have been developed and performance characteristics determined by PhenoPath Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined that such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. PhenoPath Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.